Literature DB >> 9223483

Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

C L Halbert1, T A Standaert, M L Aitken, I E Alexander, D W Russell, A D Miller.   

Abstract

The ability of recombinant adeno-associated virus (AAV) vectors to integrate into the host genome and to transduce nondividing cells makes them attractive as vehicles for gene delivery. In this study, we assessed the ability of several AAV vectors to transduce airway cells in rabbits by measuring marker gene expression. AAV vectors that transferred either a beta-galactosidase (beta-gal) or a human placental alkaline phosphatase (AP) gene were delivered to one lobe of the rabbit lung by use of a balloon catheter placed under fluoroscopic guidance. We observed vector-encoded beta-gal or AP staining almost exclusively in the epithelial and smooth muscle cells in the bronchus at the region of balloon placement. The overall efficiency of transduction in the balloon-treated bronchial epithelium was low but reached 20% in some areas. The majority of the staining was in ciliated cells but was also observed in basal cells and airway smooth muscle cells. We observed an 80-fold decrease in marker-positive epithelial cells during the 60-day period after vector infusion, whereas the number of marker-positive smooth muscle cells stayed constant. Although treatment with the topoisomerase inhibitor etoposide dramatically enhanced AAV transduction in primary airway epithelial cells in culture, treatment of rabbits did not improve transduction rates in the airway. Vector readministration failed to produce additional transduction events, which correlated with the appearance of neutralizing antibodies. These results indicate that both readministration and immune modulation will be required in the use of AAV vectors for gene therapy to the airway epithelium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223483      PMCID: PMC191849     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.

Authors:  D G Miller; M A Adam; A D Miller
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

2.  Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway.

Authors:  M J Goldman; J M Wilson
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

3.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.

Authors:  K J Fisher; G P Gao; M D Weitzman; R DeMatteo; J F Burda; J M Wilson
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

4.  Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells.

Authors:  C L Halbert; I E Alexander; G M Wolgamot; A D Miller
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

5.  Alveolar stem cell transduction by an adeno-associated viral vector.

Authors:  P L Zeitlin; S Chu; C Conrad; U McVeigh; K Ferguson; T R Flotte; W B Guggino
Journal:  Gene Ther       Date:  1995-11       Impact factor: 5.250

6.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.

Authors:  M G Kaplitt; P Leone; R J Samulski; X Xiao; D W Pfaff; K L O'Malley; M J During
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

7.  Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein.

Authors:  H Mizukami; N S Young; K E Brown
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

8.  Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.

Authors:  Y Yang; G Trinchieri; J M Wilson
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

9.  DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.

Authors:  D W Russell; I E Alexander; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans.

Authors:  B R Grubb; R J Pickles; H Ye; J R Yankaskas; R N Vick; J F Engelhardt; J M Wilson; L G Johnson; R C Boucher
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

View more
  78 in total

1.  Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina.

Authors:  J Bennett; A M Maguire; A V Cideciyan; M Schnell; E Glover; V Anand; T S Aleman; N Chirmule; A R Gupta; Y Huang; G P Gao; W C Nyberg; J Tazelaar; J Hughes; J M Wilson; S G Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination.

Authors:  J Yang; W Zhou; Y Zhang; T Zidon; T Ritchie; J F Engelhardt
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 3.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

4.  Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.

Authors:  M Moskalenko; L Chen; M van Roey; B A Donahue; R O Snyder; J G McArthur; S D Patel
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain.

Authors:  Mihail Y Mastakov; Kristin Baer; C Wymond Symes; Claudia B Leichtlein; Robert M Kotin; Matthew J During
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20.

Authors:  Dustin M McCraw; Jason K O'Donnell; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Virology       Date:  2012-06-09       Impact factor: 3.616

7.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

8.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

9.  Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

Authors:  Carmen S Peden; Fredric P Manfredsson; Sharon K Reimsnider; Amy E Poirier; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

10.  Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6.

Authors:  Qing Xie; Heather M Ongley; Joan Hare; Michael S Chapman
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.